Bank of Nova Scotia acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 206,814 shares of the medical research company's stock, valued at approximately $103,688,000. Bank of Nova Scotia owned 0.06% of Thermo Fisher Scientific as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Legacy Wealth Managment LLC ID lifted its stake in shares of Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after purchasing an additional 22 shares during the period. Kilter Group LLC acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $25,000. Allied Private Wealth LLC bought a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $26,000. High Note Wealth LLC increased its position in shares of Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock valued at $27,000 after buying an additional 29 shares in the last quarter. Finally, Swiss RE Ltd. acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $28,000. 89.23% of the stock is owned by institutional investors.
Thermo Fisher Scientific Stock Up 0.2%
Shares of TMO stock opened at $629.02 on Friday. The firm's 50-day moving average is $542.53 and its 200-day moving average is $509.70. The stock has a market cap of $232.58 billion, a price-to-earnings ratio of 33.84, a PEG ratio of 2.56 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is 10.11%.
Insiders Place Their Bets
In related news, VP Lisa P. Britt sold 11,440 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the sale, the vice president owned 14,784 shares of the company's stock, valued at $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Joseph R. Holmes sold 420 shares of the firm's stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 63,493 shares of company stock worth $37,657,681. 0.33% of the stock is currently owned by insiders.
Analysts Set New Price Targets
TMO has been the subject of several research reports. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 price objective for the company. Stifel Nicolaus set a $650.00 target price on Thermo Fisher Scientific in a research report on Wednesday, August 5th. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They set a "market perform" rating and a $520.00 price target for the company. KeyCorp restated an "overweight" rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Finally, Royal Bank Of Canada boosted their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus target price of $619.41.
View Our Latest Report on TMO
Thermo Fisher Scientific Profile
(
Free Report)
Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
